Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* are at least 65 years of age at screening;~* sign written informed consent after the scope and~nature of the investigation have been explained to~them, before screening evaluations;~* are able to speak, read and understand the language of~the investigator, study staff (including raters) and the~informed consent form, and possess the ability to~respond to questions, follow instructions and complete~questionnaires;~* have demonstrated capability to independently~complete the LogPad questionnaires and have~completed the questionnaires at least 6 out of 7 days of~the week preceding randomization;~* have a regular sleep pattern, meaning bedtime regularly~occurs between 2100 hours and 2400 hours, with no more variation~from these boundaries than 2 times/ week, with 5-8.5~hours in bed;~* have a documented diagnosis of chronic primary~insomnia, defined as fulfillment of the Diagnostic and Statistical Manual of Mental Disorders IV - Text Revision (DSM-IV-TR) criteria~for primary insomnia (DSM-IV-TR 307.42) with a duration~of \>= 1 month; fulfill the following PSG criteria on the~two screening/baseline PSG nights:~* average Total Sleep Time (TST) \< 6.5 h (and each night greater than or~equal to 3 h and \< 7 h),~* average WASO greater than or equal to 45 minutes~(and each night greater than or equal to 30 min),~* average Latency to Persistent Sleep (LPS) 15 min (and each night greater than or~equal to 10 min).~Exclusion Criteria:~* have other sleep disorders (DSM-IV-TR), such as sleep~related breathing disorders Apnea-Hypopnea Index (AHI) greater than or equal~to 15), Periodic Leg Movements with Arousals Index (PLMAI)~greater than or equal to 10), restless leg syndrome,~narcolepsy, circadian sleep wake rhythm disorders,~Rapid Eye Movement (REM) behavioral disorder or any parasomnia;~* have any significant medical or DSM-IV-TR~psychiatric illness causing the sleep disturbances;~* currently meet diagnostic criteria for DSM-IV-TR~depression Major Depressive Disorder (MDD) or have been diagnosed and treated~for MDD within the last 2 years;~* have a history of bipolar disorder, a history of suicide attempt or a family history of suicide. A family history of suicide is defined as any history of suicide in the first and second degree family (parents, siblings, grandparents, or offspring), or a pattern of completed suicides (more than one) in the third degree family (aunts, uncles, nieces and nephews);~* have a history or signs of dementia or other serious~cognitive impairment, as defined by a score of less than~26 on the Mini-Mental State Examination;~* have a significant, unstable medical illness e.g. acute or~chronic pain, hepatic, renal, metabolic or cardiac~disease;~* had serious head injury or stroke within the past year,~or a history of (non-febrile) seizures;~* have clinically relevant electrocardiogram (ECG) abnormalities at~screening, as judged by the investigator;~* have clinically relevant abnormal hematology or~biochemistry values at screening, as judged by the~investigator;~* have DSM-IV-TR substance abuse or DSM-IV-TR~addiction within the last year;~* drink more than 2 alcoholic drinks in a day. One drink is approximately equal to: 12 oz or 360 ml of beer (regular or light), or 4 oz or 120 ml of red or white wine, or 2 oz or 60 ml of desert wine (e.g. port, sherry), or 12 oz or 360 ml of wine cooler (regular or light), or 1 oz or 30 ml or spirits (80 to 100 proof, e.g. whiskey, vodka);~* are routinely sleeping during daytime (napping) for more than 20 minutes per day, 3 days or more per week;~* are night workers or rotating shift workers currently, or in the past 6 months~* use of psychotropic drugs affecting sleep within two weeks prior to randomization (fluoxetine: five weeks);~* use of concomitant medication affecting sleep (e.g. anxiolytics, sedatives, antidepressants, antipsychotics, centrally active sedating antihistamines, central nervous system (CNS)~stimulants, alpha-2-antagonists, respiratory stimulants and decongestants);~* smoke \> 15 cigarettes per day and/or can not abstain from smoking during the night;~* drink excessive amounts of caffeinated beverages/day (more than 500 mg caffeine per day);~* have a body mass index (BMI) \>= 36;~* have a positive urine drug screen at screening or at baseline;~* have a known hypersensitivity to mirtazapine or to any of the excipients;

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Esmirtazapine 0.5 mg (Type: EXPERIMENTAL): one placebo tablet daily for 14 days, followed by one 0.5 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
- Esmirtazapine 1.5 mg (Type: EXPERIMENTAL): one placebo tablet daily for 14 days, followed by one 1.5 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
- Esmirtazapine 3.0 mg (Type: EXPERIMENTAL): one placebo tablet daily for 14 days, followed by one 3.0 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): one placebo tablet daily for 14 days, followed by one placebo tablet daily for 16 days, and then one placebo tablet daily for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).